OncoHost Unveils Groundbreaking Research at ISLB 2026 for Detecting Immunotherapy Resistance Early
OncoHost Unveils Groundbreaking Research at ISLB 2026 for Detecting Immunotherapy Resistance Early
Overview
OncoHost, a pioneer in precision oncology leveraging proteomics to develop biomarkers, is preparing to present significant findings at the International Society of Liquid Biopsy (ISLB) meeting scheduled for November 7th to 9th, 2026, in Madrid, Spain. The company’s research focuses on the potential of longitudinal plasma proteomics to monitor immunotherapy effectiveness, identify emerging treatment resistance, and detect disease progression ahead of traditional imaging methods in patients suffering from advanced non-small cell lung cancer (NSCLC).
Research Highlights
In the presented abstract titled "Longitudinal Plasma Proteomic Profiling Predicts Immunotherapy Response Dynamics and Overall Survival (OS) in NSCLC," OncoHost will share insights based on a study involving 440 serial plasma samples harvested from 109 advanced NSCLC patients undergoing various immune checkpoint inhibitor (ICI) treatments. The study has developed a unique 22-protein plasma signature that is instrumental in tracking treatment response over time.
"Plasma proteomics provides an unprecedented opportunity to observe biological alterations occurring throughout cancer treatment," stated Dr. Michal Harel, VP of Translational Medicine at OncoHost. The findings indicate that these longitudinal protein signatures not only reflect treatment efficacy but also serve as early indicators of resistance, extending the ability of clinicians to provide timely and tailored care.
Significance of Findings
One of the most compelling results from the study reveals that the proteomic score was significantly associated with radiologic responses in both independent treatment cohorts. Even more striking is the fact that among patients who developed acquired resistance, changes indicating progressive disease were detected a median of 170 days (approximately 5.6 months) prior to conventional imaging methods confirming disease progression. This underscores the potential of plasma proteomics to significantly expedite clinical interventions and improve patient outcomes.
Researchers also noted distinct proteomic trajectories correlated with clinical outcomes. For instance, patterns indicating resistance were observed in 72% of patients who experienced disease progression, while those exhibiting decreasing proteomic scores enjoyed considerably better overall survival statistics, highlighting the prognostic value of continuous proteomic monitoring.
Future Implications
OncoHost envisions plasma proteomics becoming integral to personalized oncology, potentially transforming the landscape from treatment selection to continuous patient monitoring throughout therapy. Dr. Ofer Sharon, CEO of OncoHost, emphasized, "Our goal is to incorporate plasma proteomics into routine cancer care, aiding clinicians in making informed, timely decisions based on patients' evolving responses to therapy."
This innovative approach could revolutionize the treatment of NSCLC, enabling healthcare providers to stay one step ahead in managing therapy-related challenges and improving quality of life for patients.
Presentation Details
- - Title: Longitudinal Plasma Proteomic Profiling Predicts Immunotherapy Response Dynamics and Overall Survival (OS) in NSCLC
- - Session: Poster Tour
- - Poster Number: PT01.02
- - Abstract Number: 265
- - Date & Time: Saturday, November 7, 2026, from 3:15 PM to 4:00 PM
The significant findings reported by OncoHost are still in the investigational phase, necessitating further prospective validation to fully establish the clinical utility of their longitudinal proteomics monitoring signature.
About OncoHost
Based in Binyamina, Israel, and Cary, North Carolina, OncoHost is at the forefront of advancing precision medicine aimed at enhancing patient outcomes. With a proprietary platform known as PROphet®, OncoHost employs plasma-based proteomic analysis to guide critical immunotherapy decision-making for individuals diagnosed with non-small cell lung cancer. This innovation has showcased a substantial impact on overall patient survival rates. With a robust support system that includes a large-scale prospective clinical trial involving over 1,700 patients across more than 40 sites, OncoHost is positioned to lead the charge in precision diagnostics and biomarker advancement.
For further information on OncoHost and its innovative research platforms, please visit OncoHost.com or follow them on their social media accounts.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.